Use of chromosome painting for detecting stable chromosome aberrations induced by melphalan in mice

Environmental and Molecular Mutagenesis

Volumn 45, Issue 5, 2005, Pages 419-426

  Sgura, Antonella ^a   Stronati, Laura ^b   Gullotta, Francesco ^a   Pecis, Andrea ^b   Cinelli, Serena ^c   Lascialfari, Antonella ^c   Tanzarella, Caterina ^a   Pacchierotti, Francesca ^b  

^a ROMA TRE UNIVERSITY   (Italy)

^b ENEA   (Italy)

^c Research Toxicology Center   (Italy)

Author keywords

Bone marrow cells; Chromosome aberrations; Chromosome painting; Mouse; Splenocytes

Indexed keywords

CARCINOGEN; MELPHALAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW; CARCINOGENESIS; CELL PROLIFERATION; CHROMOSOME ABERRATION; CHROMOSOME PAINTING; CHROMOSOME TRANSLOCATION; CONTROLLED STUDY; DOSE RESPONSE; GENOMIC INSTABILITY; GENOTOXICITY; MALIGNANT TRANSFORMATION; MITOSIS; MOUSE; NONHUMAN; SOMATIC CELL; SPLEEN;

ANIMALS; BONE MARROW CELLS; CHROMOSOME ABERRATIONS; CHROMOSOME PAINTING; CYTOGENETIC ANALYSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; MELPHALAN; MICE; MICE, MUTANT STRAINS; SPLEEN;

EID: 21244441167     PISSN: 08936692     EISSN: None     Source Type: Journal    
DOI: 10.1002/em.20107     Document Type: Article

References (53)

1. Amiel A, Fridman K, Elis A, Gaber E, Manor Y, Fejgin M, Lishner M. 1999. Deletion 5q31 in patients with stable melphalan-treated multiple myeloma. Cancer Genet Cytogenet 113:45-48.
2. Amiel A, Yukla M, Yogev S, Manor Y, Fejgin MD, Lishner M. 2004. Deletion of 5q31 and 7q31 in patients with stable melphalan-treated multiple myeloma. Cancer Genet Cytogenet 152:84-87.
3. Anderson D, Jenkinson PC, Dewdney RS, Francis AJ, Godbert P, Butterworth KR. 1988. Chromosome aberrations, mitogen-induced blastogenesis and proliferative rate index in peripheral lymphocytes from 106 control individuals of the U.K. population. Mutat Res 204:407-420.
4. Bauchinger M. 1997. Health impacts of large releases of radionuclides: cytogenetic effects as quantitative indicators of radiation exposure. Ciba Found Symp 203:188-199.
5. Bauchinger M, Schmid E, Braselmann H. 2001. Time-course of translocation and dicentric frequencies in a radiation accident case. Int J Radiat Biol 77:553-557.
6. Bonassi S, Au WW. 2002. Biomarkers in molecular epidemiology studies for health risk prediction. Mutat Res 511:73-86.
7. Breneman JW, Briner JF, Ramsey MJ, Director A, Tucker JD. 1996. Cytogenetic results from a chronic feeding study of MeIQx in mice. Food Chem Toxicol 34:717-724.
8. Choi KE, Ratain MJ, Williams SF, Golick JA, Beschorner JC, Fullem LJ, Bitran JD. 1989. Plasma pharmacokinetics of high-dose oral melphalan in patients treated with trialkylator chemotherapy and autologous bone marrow reinfusion. Cancer Res 49:1318-1321.
9. Cremer T, Lichter P, Borden J, Ward DC, Manuelidis L. 1988. Detection of chromosome aberrations in metaphase and interphase tumour cells by in situ hybridization using chromosome-specific library probes. Hum Genet 80:235-246.
10. Crossen PE. 1989. Cytogenetic and molecular changes in chronic B-cell leukemia. Cancer Genet Cytogenet 43:143-150.
11. Dewald GW, Brockman SR, Paternoster SF, Bone ND, O'Fallon JR, Allmer C, James CD, Jelinek DF, Tschumper RC, Hanson CA, Pruthi RK, Witzig TE, Call TG, Kay NE. 2003. Chromosome anomalies detected by interphase fluorescence in situ hybridization: correlation with significant biological features of B-cell chronic lymphocytic leukaemia. Br J Haematol 121:287-295.
12. Director AE, Nath J, Ramsey MJ, Swiger RR, Tucker JD. 1996. Cytogenetic analysis of mice chronically fed the food mutagen 2-amino-1-methyl-6- phenylimidazo[4,5b]pyridme. Mutat Res 359:53-61.
13. Director AE, Tucker JD, Ramsey MJ, Nath J. 1998. Chronic ingestion of clastogens by mice and the frequency of chromosome aberrations. Environ Mol Mutagen 32:139-147.
14. Emanuel BS, Shaikh TH. 2001. Segmental duplications: an "expanding" role in genomic instability and disease. Nat Rev Genet 2:791-800.
15. Fauth E, Scherthan H, Zankl H. 2000. Chromosome painting reveals specific patterns of chromosome occurrence in mitomycin C- and diethylstilboestrol- induced micronuclei. Mutagenesis 15:459-467.
16. Generoso WM, Witt KL, Cain KT, Hughes L, Cacheiro NL, Lockhart AM, Shelby MD. 1995. Dominant lethal and heritable translocation tests with chlorambucil and melphalan in male mice. Mutat Res 345:167-180.
17. Gulezian D, Jacobson-Kram D, McCullough CB, Olson H, Recio L, Robinson D, Storer R, Tennant R, Ward JM, Neumann DA. 2000. Use of transgenic animals for carcinogenicity testing: considerations and implications for risk assessment. Toxicol Pathol 28:482-499.
18. Hagmar L, Bonassi S, Stromberg U, Brogger A, Knudsen LE, Norppa H, Reuterwall C. 1998. Chromosomal aberrations in lymphocytes predict human cancer: a report from the European Study Group on Cytogenetic Biomarkers and Health (ESCH). Cancer Res 58:4117-4121.
19. Henne T, Schmahl D. 1985. Occurrence of second primary malignancies in man: a second look. Cancer Treat Rev 12:77-94.
20. Hennings H, Click AB, Lowry DT, Krsmanovic LS, Sly LM, Yuspa SH. 1993. FVB/N mice: an inbred strain sensitive to the chemical induction of squamous cell carcinomas in the skin. Carcinogenesis 14:2353-2358.
21. Herzig M, Christofori G. 2002. Recent advances in cancer research: mouse models of tumorigenesis. Biochim Biophys Acta 1602:97-113.
22. International Agency for Research on Cancer. 1987. Overall evaluations of carcinogenicity: an updating of IARC Monographs volumes 1 to 42. IARC Monogr Eval Carconog Risks Hum 7(Suppl):1-440.
23. Lambert B, Holmberg K, Einhorn N. 1986. Chromosome damage and second malignancy in patients treated with melphalan. IARC Sci Publ 78:147-160.
24. Lindholm C. 2001. Stable and unstable chromosomal aberrations among Finnish nuclear power plant workers. Radiat Prot Dosimetry 93:143-150.
25. Lucas JN, Tenjin T, Straume T, Pinkel D, Moore D, Litt M, Gray JW. 1989. Rapid human chromosome aberration analysis using fluorescence in situ hybridization. Int J Radiat Biol 56:35-44.
26. Lucas JN, Awa A, Straume T, Poggensee M, Kodama Y, Nakano M, Ohtaki K, Weier HU, Pinkel D, Gray J. 1992. Rapid translocation frequency analysis in humans decades after exposure to ionizing radiation. Int J Radiat Biol 62:53-63.
27. Lucas JN, Sachs RK. 1993. Using three-color chromosome painting to test chromosome aberration models. Proc Natl Acad Sci USA 90:1484-1487.
28. Mamuris Z, Prieur M, Dutrillaux B, Aurias A. 1989a. The chemotherapeutic drug melphalan induces breakage of chromosomes regions rearranged in secondary leukemias. Cancer Genet Cytogenet 37:65-77.
29. Mamuris Z, Prieur M, Dutrillaux B, Aurias A. 1989b. Specificity of melphalan-induced rearrangements and their transmission through cell divisions. Mutagenesis 4:133-139.
30. Mamuris Z, Gerbault-Seureau M, Prieur M, Pouillart P, Dutrillaux B, Aurias A. 1989c. Chromosomal aberrations in lymphocytes of patients treated with melphalan. Int J Cancer 43:80-86.
31. Marchetti F, Bishop JB, Cosentino L, Moore D II, Wyrobek AJ. 2004. Paternally transmitted chromosomal aberrations in mouse zygotes determine their embryonic fate. Biol Reprod 70:616-624.
32. Marshall R, Obe G. 1998. Application of chromosome painting to clastogenicity testing in vitro. Environ Mol Mutagen 32:212-222.
33. Mitsumori K. 2002. Evaluation on carcinogenicity of chemicals using transgenic mice. Toxicology 181-182:241-244.
34. Morita M, Minowada J, Sandberg AA. 1981. Chromosomes and causation of human cancer and leukemia: XLV, chromosome patterns in stimulated lymphocytes of chronic lymphocytic leukemia. Cancer Genet Cytogenet 3:293-306.
35. Natarajan AT, Vyas RC, Darroudi F, Vermeulen S. 1992. Frequencies of X-ray-induced chromosome translocations in human peripheral lymphocytes as detected by in situ hybridization using chromosome-specific DNA libraries. Int J Radiat Biol 61:199-203.
36. Qiu H, Shimada K, Cheng Z. 1992. Chromosomal localization of the mouse prealbumin gene (Ttr) by in situ hybridization. Cytogenet Cell Genet 61:186-188.
37. Rabbitts TH. 1994. Chromosomal translocations in human cancer. Nature 372:143-149.
38. Ramsey MJ, Nagao M, Inoue R, Fujita H, Matsushima T, Tucker JD. 1998. Chromosome aberrations induced in mice by chronic feeding of 2-amino-3,4-dimethylimidazo[4,5-f]quinoline (MeIQ). Food Chem Toxicol 36:467-474.
39. Robinson D. 1998. The International Life Sciences Institute's role in the evaluation of alternative methodologies for the assessment of carcinogenic risk. Toxicol Pathol 26:474-475.
40. Russell LB, Hunsicker PR, Shelby MD. 1992a. Melphalan, a second chemical for which specific-locus mutation induction in the mouse is maximum in early spermatids. Mutat Res 282: 151-158.
41. Russell LB, Hunsicker PR, Cacheiro NL, Rinchik EM. 1992b. Genetic, cytogenetic, and molecular analyses of mutations induced by melphalan demonstrate high frequencies of heritable deletions and other rearrangements from exposure of postspermatogonial stages of the mouse. Proc Natl Acad Sci USA 89:6182-6186.
42. Sandberg AA. 1980. Chromosomes and causation of human cancer and leukemia: XL, the Ph1 and other translocations in CML. Cancer 46:2221-2226.
43. Sharpe HB. 1971. Observations on the effect of therapy with nitrogen mustrad or a derivative on chromosomes of human peripheral blood lymphocytes. Cell Tissue Kinet 4:501-504.
44. Shelby MD, Gulati DK, Tice R, Wajciechowskj JP. 1989. Results of tests for micronuclei and chromosomal aberrations in mouse bone marrow cells with the human carcinogens 4-aminobiphenyl, treosulphalan, and melphalan. Environ Mol Mutagen 13:339-342.
45. Solomon E, Borrow J, Goddard AD. 1991. Chromosome aberrations and cancer. Science 254:1153-1160.
46. Spruill MD, Ramsey MJ, Swiger RR, Nath J, Tucker JD. 1996. The persistence of aberrations in mice induced by gamma radiation as measured by chromosome painting. Mutat Res 356:135-145.
47. Stronati L, Farris A, Pacchierotti F. 2004. Evaluation of chromosome painting to assess the induction and persistence of chromosome aberrations in bone marrow cells of mice treated with benzene. Mutat Res 545:1-9.
48. Taketo M, Schroeder AC, Mobraaten LE, Gunning KB, Hanten G, Fox RR, Roderick TH, Stewart CL, Lilly F, Hansen CT, et al. 1991. FVB/N: an inbred mouse strain preferable for transgenic analyses. Proc Natl Acad Sci USA 88:2065-2069.
49. Tucker JD, Morgan WF, Awa AA, Bauchinger M, Blakey D, Cornforth MN, Littlefield LG, Natarajan AT, Shasserre C. 1995. A proposed system for scoring structural aberrations detected by chromosome painting. Cytogenet Cell Genet 68:211-221.
50. Tucker JD. 1998. The use of chromosome translocations for measuring prior environmental exposures in humans. In: Mendelsohn M, Mohr L, Peeters J, editors. Biomarkers: medical and workplace applications. Washington, DC: Joseph Henry Press. p 117-132.
51. Tycko B, Sklar J. 1990. Chromosomal translocations in lymphoid neoplasia: a reappraisal of the recombinase model. Cancer Cells 2:1-8.
52. Wang ZM, Chen ZP, Xu ZY, Christodoulopoulos G, Bello V, Mohr G, Aloyz R, Panasci LC. 2001. In vitro evidence for homologous recombinational repair in resistence to melphalan. J Natl Cancer Inst 93:1473-1478.
53. Wantzin GL, Jensen MK. 1973. The induction of chromosome abnormalities by melphalan in rat bone marrow cells. Scand J Haematol 11:135-139.